Abstract

Conventional manufacturing of protein biopharmaceuticals in centralized, large-scale, single-product facilities is not well-suited to the agile production of drugs for small patient populations or individuals. Previous solutions for small-scale manufacturing are limited in both process reproducibility and product quality, owing to their complicated means of protein expression and purification1,2,3,4. We describe an automated, benchtop, multiproduct manufacturing system, called Integrated Scalable Cyto-Technology (InSCyT), for the end-to-end production of hundreds to thousands of doses of clinical-quality protein biologics in about 3 d. Unlike previous systems, InSCyT includes fully integrated modules for sustained production, efficient purification without the use of affinity tags, and formulation to a final dosage form of recombinant biopharmaceuticals. We demonstrate that InSCyT can accelerate process development from sequence to purified drug in 12 weeks. We used integrated design to produce human growth hormone, interferon α-2b and granulocyte colony-stimulating factor with highly similar processes on this system and show that their purity and potency are comparable to those of marketed reference products.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Point-of-care production of therapeutic proteins of good-manufacturing-practice quality. Nat. Biomed. Eng. (2018).

  2. 2.

    et al. Digital-to-biological converter for on-demand production of biologics. Nat. Biotechnol. 35, 672–675 (2017).

  3. 3.

    et al. Portable, on-demand biomolecular manufacturing. Cell 167, 248–259.e12 (2016).

  4. 4.

    et al. Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care. Nat. Commun. 7, 12211 (2016).

  5. 5.

    & Precision medicine: an approach to R&D for delivering superior medicines to patients. Clin. Transl. Med. 1, 7 (2012).

  6. 6.

    Anonymous. Patient-centered drug manufacture. Nat. Biotechnol. 35, 485 (2017).

  7. 7.

    , , & Making individualized drugs a reality. Nat. Biotechnol. 35, 507–513 (2017).

  8. 8.

    et al. Comparative genomics and transcriptomics of Pichia pastoris. BMC Genomics 17, 550 (2016).

  9. 9.

    , , & Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl. Microbiol. Biotechnol. 98, 5301–5317 (2014).

  10. 10.

    Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313, 1441–1443 (2006).

  11. 11.

    & White paper on continuous bioprocessing. May 20–21 2014 Continuous Manufacturing Symposium. J. Pharm. Sci. 104, 813–820 (2015).

  12. 12.

    Genentech Inc. Nutropin prescribing information. (2016).

  13. 13.

    Center for Biologics Evaluation and Research & Center for Drug Evaluation and Research. Guidance for industry: for the submission of chemistry, manufacturing, and controls information for a therapeutic recombinant DNA-derived product or a monoclonal antibody product for in vivo use. (1996).

  14. 14.

    The European Agency for the Evaluation of Medicinal Products. CPMP position statement on DNA and host cell proteins (HCP) impurities, routine testing versus validation studies. (1997).

  15. 15.

    et al. Evaluating immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics. AAPS J. 18, 1439–1452 (2016).

  16. 16.

    World Health Organization. Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. (2013).

  17. 17.

    et al. Properties of a cleaved two-chain form of recombinant human growth hormone. Int. J. Pept. Protein Res. 35, 17–24 (1990).

  18. 18.

    Merck & Co. Inc. Intron A product information 1–39 (1986).

  19. 19.

    et al. Reexamining opportunities for therapeutic protein production in eukaryotic microorganisms. Biotechnol. Bioeng. 114, 2432–2444 (2017).

  20. 20.

    et al. An impurity characterization based approach for the rapid development of integrated downstream purification processes. Biotechnol. Bioeng. 115, 2048–2060 (2018).

  21. 21.

    & C-terminally truncated interferon. US Patent US20090025106A1 (2011).

  22. 22.

    et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 22, 1997–2006 (2005).

  23. 23.

    et al. N-terminal or signal peptide sequence engineering prevents truncation of human monoclonal antibody light chains. Biotechnol. Bioeng. 114, 1970–1977 (2017).

  24. 24.

    Amgen Inc. Neupogen prescribing information. (2015).

  25. 25.

    et al. Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry 41, 6422–6431 (2002).

  26. 26.

    et al. Chemical modification and site-directed mutagenesis of methionine residues in recombinant human granulocyte colony-stimulating factor: effect on stability and biological activity. Arch. Biochem. Biophys. 362, 1–11 (1999).

  27. 27.

    et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)—results of a prospective randomised monocentre study. Bone Marrow Transplant. 28, 259–264 (2001).

  28. 28.

    et al. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs 29, 123–131 (2015).

  29. 29.

    et al. On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science 352, 61–67 (2016).

  30. 30.

    US Food and Drug Administration. Points to consider in the manufacture and testing of monoclonal antibody products for human use (US Government Publishing Office, 1997).

  31. 31.

    , , & Development of a general defined medium for Pichia pastoris. Biotechnol. Bioeng. 115, 103–113 (2018).

  32. 32.

    , & Enzyme-Linked Immunosorbent Assays (ELISA). in Curr. Protoc. Mol. Biol. 11.2.1–11.2.22 (Wiley, 1991).

  33. 33.

    et al. Integrated bottom-up and top-down liquid chromatography-mass spectrometry (LC-MS) for characterization of recombinant human growth hormone degradation products. Anal. Chem. (2017).

  34. 34.

    United States Department of Agriculture (USDA). Animal and Plant Health Inspection Service. 9 CFR Ch. 1, Subchapter A - Animal Welfare (US Government Publishing Office, 2013).

  35. 35.

    Office for Laboratory Animal Welfare (OLAW). Public Health Service policy on humane care and use of laboratory animals. Health Research Extension Act of 1985 (US Government Publishing Office, 1985).

  36. 36.

    National Research Council. Guide for the Care and Use of Laboratory Animals. (National Academies Press, 2011).

  37. 37.

    Biological Evaluation of Medical Devices - Part 2: Animal Welfare Requirements ISO 10993-2 (International Organization for Standardization, 2006).

  38. 38.

    Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. (2018).

Download references

Acknowledgements

This work was supported in part by the Defense Advanced Research Projects Agency (DARPA) and SPAWAR System Center Pacific (SSC Pacific) under contract no. N66001-13-C-4025. This work was also supported in part by the Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute and funding from the Department of Chemical Engineering, School of Engineering, Massachusetts Institute of Technology. J.R.B., N.C.D. and N.J.M. were supported by a NIGMS/MIT Biotechnology Training Program Fellowship under NIH contract no. 2T32GM008334-26. K.A.S. was supported by a Mazumdar Shaw International Fellowship. J.C.L. is a Camille Dreyfus Teacher-Scholar. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, NIH, DARPA or SSC Pacific.

Author information

Author notes

    • Laura E Crowell
    • , Amos E Lu
    •  & Kerry R Love

    These authors contributed equally to this work.

Affiliations

  1. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Laura E Crowell
    • , Kerry R Love
    • , Alan Stockdale
    • , William Doherty
    • , Alexandra Bonnyman
    • , Joseph R Brady
    • , John J Clark
    • , Noelle A Colant
    • , Neil C Dalvie
    • , Diana Liu
    • , Craig A Mascarenhas
    • , Catherine B Matthews
    • , Nicholas J Mozdzierz
    • , Kartik A Shah
    •  & J Christopher Love
  2. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Laura E Crowell
    • , Amos E Lu
    • , Joseph R Brady
    • , Noelle A Colant
    • , Neil C Dalvie
    • , Catherine B Matthews
    • , Nicholas J Mozdzierz
    • , Richard D Braatz
    •  & J Christopher Love
  3. Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.

    • Steven M Timmick
    • , Nicholas Vecchiarello
    • , Chaz Goodwine
    •  & Steven M Cramer
  4. Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York, USA.

    • Steven M Timmick
    • , Nicholas Vecchiarello
    • , Chaz Goodwine
    •  & Steven M Cramer
  5. GlaxoSmithKline, King of Prussia, Pennsylvania, USA.

    • Steven M Timmick
  6. Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA.

    • Di Wu
    • , Yu (Annie) Wang
    • , Yanjun Liu
    •  & William S Hancock
  7. Pall Life Sciences, Westborough, Massachusetts, USA.

    • Lisa Bradbury
    •  & Aleksandar Cvetkovic
  8. Biogen, Cambridge, Massachusetts, USA.

    • John J Clark
  9. Department of Biochemical Engineering, University College London, London, England.

    • Noelle A Colant
  10. Sanofi, Framingham, Massachusetts, USA.

    • Aleksandar Cvetkovic
  11. Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Craig A Mascarenhas
  12. BioAnalytix Inc., Cambridge, Massachusetts, USA.

    • Shiaw-Lin Wu

Authors

  1. Search for Laura E Crowell in:

  2. Search for Amos E Lu in:

  3. Search for Kerry R Love in:

  4. Search for Alan Stockdale in:

  5. Search for Steven M Timmick in:

  6. Search for Di Wu in:

  7. Search for Yu (Annie) Wang in:

  8. Search for William Doherty in:

  9. Search for Alexandra Bonnyman in:

  10. Search for Nicholas Vecchiarello in:

  11. Search for Chaz Goodwine in:

  12. Search for Lisa Bradbury in:

  13. Search for Joseph R Brady in:

  14. Search for John J Clark in:

  15. Search for Noelle A Colant in:

  16. Search for Aleksandar Cvetkovic in:

  17. Search for Neil C Dalvie in:

  18. Search for Diana Liu in:

  19. Search for Yanjun Liu in:

  20. Search for Craig A Mascarenhas in:

  21. Search for Catherine B Matthews in:

  22. Search for Nicholas J Mozdzierz in:

  23. Search for Kartik A Shah in:

  24. Search for Shiaw-Lin Wu in:

  25. Search for William S Hancock in:

  26. Search for Richard D Braatz in:

  27. Search for Steven M Cramer in:

  28. Search for J Christopher Love in:

Contributions

L.E.C., A.E.L. and K.R.L. designed experiments, analyzed data and wrote the manuscript. J.C.L., K.R.L., R.D.B., A.S., A.E.L., N.J.M. and L.E.C. designed and built the InSCyT system. A.E.L. and R.D.B. developed controls for the InSCyT system. L.E.C., W.D. and A.B. performed experiments on the InSCyT system and performed quality assessments. D.W., Y.A.W., Y.L., S.-L.W. and W.S.H. assessed quality by mass spectrometry and isoelectric focusing. S.M.T., N.V., C.G. and S.M.C. developed the purification processess and assessed quality by RPLC, size exclusion chromatography and CD. J.R.B., N.C.D. and K.R.L. developed and performed product-specific ELISAs. K.R.L., K.A.S., N.J.M. and J.R.B. engineered the strains used in production. J.J.C., N.A.C., D.L., C.A.M., C.B.M., N.J.M. and K.R.L. contributed to development of upstream processes. A.C. and L.B. developed the purification process for hGH. J.C.L., S.M.C., R.D.B. and W.S.H. designed the experimental strategy, supervised analysis and wrote the manuscript. All authors reviewed the manuscript.

Competing interests

The authors have filed patents related to this work.

Corresponding author

Correspondence to J Christopher Love.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–11

  2. 2.

    Life Sciences Reporting Summary

  3. 3.

    Supplementary Tables

    Supplementary Tables 1–4

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt.4262